Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REPLIGEN CORPORATION

(RGEN)
  Report
Delayed Quote. Delayed Nasdaq - 11/26 01:00:00 pm
286.01 USD   +5.21%
11/22INSIDER SELL : Repligen
MT
11/17REPLIGEN CORPORATION : Technically solid
11/15INSIDER SELL : Repligen
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Repligen : Extends Long Term Supply Agreement with Cytiva for Affinity Ligands

09/06/2021 | 10:11am EST

WALTHAM, MA - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, announced that it has extended through 2025 a long-term supply agreement with Cytiva for the manufacture of ligands at the Company's facilities in Waltham, MA and Lund, Sweden. The agreement maintains Repligen as a key strategic supplier to Cytiva.

Kola Otitoju, Repligen's SVP Strategy and Business Development, said, 'We are very pleased to extend this partnership with Cytiva and continue our 30+ year partnership. Ligands are a very important part of our overall business strategy, where our focus is on providing these products reliably at large scale from multiple sites. By offering flexibility for strategic customers like Cytiva, we continue to differentiate ourselves in the bioprocessing marketplace.' Affinity ligands are the critical component of chromatography media that enable the affinity purification of monoclonal antibody-based biologic drugs. There are currently more than 120 monoclonal antibodies that have received U.S. FDA regulatory approval and more than 600 are at various stages of clinical development.

Contact:

T: 310.885.4600

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about REPLIGEN CORPORATION
11/22INSIDER SELL : Repligen
MT
11/15INSIDER SELL : Repligen
MT
11/12Repligen Corporation to Present at Upcoming Investor Conferences
GL
11/08Repligen Releases Inaugural Sustainability Report
AQ
11/05Repligen Releases Inaugural Sustainability Report
AQ
11/04INSIDER SELL : Repligen
MT
11/02INSIDER SELL : Repligen
MT
10/29SVB Leerink Adjusts Price Target on Repligen to $325 from $260, Keeps Outperform Rating
MT
10/28REPLIGEN CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
AQ
10/28Repligen Corporation Reports Earnings Results for the Third Quarter and Nine Months End..
CI
More news
Analyst Recommendations on REPLIGEN CORPORATION
More recommendations
Financials (USD)
Sales 2021 664 M - -
Net income 2021 128 M - -
Net cash 2021 431 M - -
P/E ratio 2021 128x
Yield 2021 -
Capitalization 15 813 M 15 813 M -
EV / Sales 2021 23,2x
EV / Sales 2022 19,3x
Nbr of Employees -
Free-Float 93,2%
Chart REPLIGEN CORPORATION
Duration : Period :
Repligen Corporation Technical Analysis Chart | RGEN | US7599161095 | MarketScreener
Technical analysis trends REPLIGEN CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 286,01 $
Average target price 318,11 $
Spread / Average Target 11,2%
EPS Revisions
Managers and Directors
Tony J. Hunt President, Chief Executive Officer & Director
Jon K. Snodgres Chief Financial Officer
Karen A. Dawes Chairman
Ralf Kuriyel Senior Vice President-Research & Development
James R. Bylund Senior Vice President-Global Operations & IT
Sector and Competitors
1st jan.Capi. (M$)
REPLIGEN CORPORATION41.86%15 813
ABBOTT LABORATORIES14.97%222 592
MEDTRONIC PLC-5.20%149 347
BECTON, DICKINSON AND COMPANY-2.05%69 611
HOYA CORPORATION27.96%59 428
DEXCOM, INC.60.11%57 374